Loyal Develops Daily Pill LOY-002 to Slow Aging in Senior Dogs Under FDA Review

San Francisco-based biotech company Loyal is developing LOY-002, a prescription pill intended to slow the biological aging process in dogs. The drug is designed for dogs aged 10 years and older that weigh more than 14 pounds. S.

Food and Drug Administration's Center for Veterinary Medicine. LOY-002 works by interacting with insulin-like growth factor 1 (IGF-1), a hormone involved in growth and metabolism. While IGF-1 supports growth in puppies, elevated levels in later life are associated with accelerated cellular aging, particularly in medium- and large-breed dogs.

By reducing IGF-1 effects, the pill aims to lower risks of age-related diseases and extend both lifespan and healthy years. Medium- and large-breed dogs typically have shorter lifespans than smaller breeds due to higher IGF-1 activity, which contributes to faster aging and organ dysfunction.

Early testing by Loyal indicates potential lifespan extension, though specific gains are still under study.

The global pet care market reached $261 billion in the previous year. LOY-002 has cleared two of the three major regulatory steps required by the FDA. Company executives stated that FDA approval for a lifespan-extending drug has been a goal since Loyal's founding six years ago.

If the final approval is granted, the pill could become available before the end of 2026. Loyal Founder and CEO Celine Halioua commented on the progress.

“Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension. This safety acceptance brings us very close to achieving that vision. We are well on our way to bringing the first dog longevity drugs to market.”

Investor Anish Moonka wrote on X that LOY-002 could mimic benefits of caloric restriction, such as delayed onset of cancer and arthritis, without reducing appetite or weight. The pill is not yet available and does not replace established care practices like regular veterinary visits, exercise, and proper nutrition for senior dogs.

The development of LOY-002 could shift veterinary approaches from treating specific age-related conditions to addressing aging as a biological process. Dog owners face challenges with chronic illnesses, mobility decline, and end-of-life decisions in aging pets.

Approval would mark the first FDA-cleared drug to slow aging in any species, according to company statements.